Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 9, Issue 3, Pages 405-420Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14656566.9.3.405
Keywords
cardiovascular outcomes; clinical trials; dyslipidaemia; glycaemia; inflammation; microalbuminuria; pioglitazone; rosiglitazone; surrogate end points; Type 2 diabetes
Categories
Ask authors/readers for more resources
The thiazolidinediones, rosiglitazone and pioglitazone are used in the treatment of Type 2 diabetes (T2DM). Both have been shown to decrease glycated haemoglobin levels, fasting plasma glucose, insulin, and free fatty acids levels in subjects with T2DM. However, these agents have markedly different effects; on lipids. Rosiglitazone increases total, low- and high-density lipoprotein (LDL. and HDL) cholesterol, and triglycerides, whereas pioglitazone has no effect on total or LDL cholesterol, increases HDL cholesterol and decreases triglycerides. Both rosiglitazone and pioglitazone decrease inflammatory markers. Furthermore, both rosiglitazone and pioglitazone may cause a small decrease in blood pressure, improve endothelial function and reduce restenosis. Microalbuminuria is also reduced by both rosiglitazone and pioglitazone. Despite the improvements in surrogate end points, there is little clear evidence that either rosiglitazone or pioglitazone cause major improvements in cardiovascular outcomes. Thus, rosiglitazone has no effect or may even increase cardiovascular outcomes, whereas, in high-risk subjects, pioglitazone has a marginal ability to decrease cardiovascular outcomes. Unless the thiazolidinediones are shown to improve cardiovascular or other outcomes (e.g., renal) in the next few years, their continued use in T2DM should be questioned.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available